Pharmacyte Biotech Inc Stock Price, News & Analysis

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) has appointed Dr. Matthias Löhr to its Board of Directors. Dr. Löhr, a leading expert in gastroenterology and oncology, is expected to enhance the company's strategic direction, especially as it approaches FDA clinical trials for pancreatic cancer. With a robust background in clinical trials and a history with PharmaCyte's technology, Dr. Löhr's involvement is anticipated to positively influence development efforts in cancer and diabetes therapies using the Cell-in-a-Box® technology.

PharmaCyte Biotech (NASDAQ: PMCB) has completed a crucial 24-month stability study for its clinical trial product candidate, CypCaps™, demonstrating a shelf life of at least 24 months at -80°C. This milestone confirms the product's viability, enzymatic activity, and cell potency, essential for its cancer therapy applications. CEO Kenneth Waggoner highlighted the study's significance for both PharmaCyte and the cell therapy sector. Data from this study will be included in PharmaCyte's updated submission to the FDA, further solidifying its position in developing cellular therapies for cancer and diabetes.

PharmaCyte Biotech (NASDAQ: PMCB) announced its Q3 financial results for the period ending January 31, 2022, revealing a cash position of approximately $87 million. The company established FDIC-insured accounts totaling around $50.3 million. Noteworthy advancements include progress in its CypCaps pancreatic cancer treatment, with recent studies confirming no toxicity of the capsule material and initiation of pivotal studies for malignant ascites. Total stockholder equity stood at about $91 million, although operating expenses increased due to R&D and public offerings.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) has announced a detailed analysis of the integration site of the cytochrome P450 2B1 gene in its pancreatic cancer product candidate, CypCaps™. Previous studies indicated the gene was located on human chromosome 9. The new findings confirm the structure of the transgene sequence and demonstrate genetic stability in cell growth. PharmaCyte aims to develop cellular therapies for cancer and diabetes using its Cell-in-a-Box® technology, which has been effective in previous clinical trials.

PharmaCyte Biotech (NASDAQ: PMCB) provided an update on its efforts to lift the FDA's clinical hold on its treatment for locally advanced pancreatic cancer. Following an Investigational New Drug Application, the FDA requested additional studies. PharmaCyte has completed several studies and is actively engaging with experts and organizations to compile required data. Challenges include global supply chain issues affecting study timelines. Key updates include the addition of regulatory expertise, successful completion of product stability studies, and commencement of various biocompatibility studies.

PharmaCyte Biotech (NASDAQ: PMCB) announced its participation as a presenting company at the virtual H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Kenneth L. Waggoner will discuss the company's business and product pipeline during the presentation, available on-demand starting January 10, 2022. Additionally, PharmaCyte plans to release an update on its clinical hold by the FDA for its Phase 2b trial targeting locally advanced pancreatic cancer. More information is available on their website.

PharmaCyte Biotech (NASDAQ: PMCB) announced findings from a recent study confirming that the capsule material in its CypCaps pancreatic cancer product is non-toxic to encapsulated cells. The evaluation showed the capsule material is bio-inert, supporting treatment for locally advanced, inoperable pancreatic cancer. Conducted in compliance with international standards, the study used mouse fibroblast cells to assess cytotoxicity, yielding positive results. This adds to PharmaCyte's goal of developing effective cancer and diabetes therapies using its unique Cell-in-a-Box technology.

PharmaCyte Biotech (NASDAQ: PMCB) has completed a significant 36-month stability study of cells from its Master Cell Bank, crucial for its treatment of locally advanced pancreatic cancer (LAPC). This study, required by the FDA to lift a clinical hold on its CypCaps product, confirms that the cells are stable and viable when stored in liquid nitrogen. The ongoing research will continue to assess the maximum shelf life of these cells. PharmaCyte plans to include findings from this study in its Complete IND Submission to the FDA.

PharmaCyte Biotech (NASDAQ: PMCB) reported its financial results for the second quarter ending October 31, 2021. The company has approximately $87 million in cash on hand and completed a $15 million public offering and a $70 million registered direct offering. Key operational highlights include advancements in its cancer and diabetes programs, stability of CypCaps™ after 18 months, and positive biocompatibility study results. Total stockholder equity rose by $86 million from July 31, 2021, while operating expenses increased due to Nasdaq uplisting and R&D investments.